Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia

Blood

Volumn 89, Issue 8, 1997, Pages 2701-2705

  Pajkrt, Dasja ^a   Van Der Poll, Tom ^b   Levi, Marcel ^b   Cutler, David L ^b   Affrime, Melton B ^b   Van Den Ende, Abraham ^b   Ten Cate, Jan Wouter ^b   Van Deventer, Sander J H ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; CYTOKINE; D DIMER; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; PLACEBO; PLASMIN; RECOMBINANT INTERLEUKIN 10; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENDOTOXEMIA; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

EID: 0030971484     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.2701     Document Type: Article

References (20)

1. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520, 1990
2. Suffredini AF, Harpel PC, Parillo JE: Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165, 1989
3. Biemond BJ, Levi M, ten Cate H, Van der Poll T, Büller HR, Hack CE, ten Cate JW: Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxemia in chimpanzees: the effects of interventions in the cytokine and coagulation cascades. Clin Sci 88:587, 1995
4. 23). Blood 85:3437, 1995
5. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 11:165, 1993
6. Howard M, O'Garra A: Biological properties of IL-10. Immunol Today 13:198, 1992
7. Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547, 1993
8. Howard M, Muchamuel T, Andrade S, Nmenon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205, 1993
9. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154:5492, 1995
10. Pajkrt D, Camoglio L, Riel-van Buul MCM, de Bruin K, Cutler DL, Affrime MB, Rikken G, van der Poll T, ten Cate JW, van Deventer SJH: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: The effect of timing of rhIL-10 administration. J Immunol (in press)
11. Ramani M, Ollivier V, Khechai F, Vu T, Ternisien C, Bridey F, de Prost D: Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes. FEBS Lett 334:114, 1993
12. Ramani M, Khechai F, Ollivier V, Ternisien C, Bridey F, Hakim J, de Prost D: Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. FEBS Lett 356:86, 1994
13. Pradier O, Gérard C, Delvaux A, Lybin M, Abramowicz D, Capel P, Velu T, Goldman M: Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 23:2700, 1993
14. Levi M, ten Cate H, Bauer KA, Büller HR, van der Poll T, van Deventer SJH, Rosenberg RD, ten Cate JW: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifyllin or by a monclonal anti-tissue factor antibody in a chimpanzee model. J Clin Invest 93:114, 1994
15. Taylor FB Jr, Chang A, Ruf W, Morrissey, Hinshaw L, Catlett R, Blick K, Edgington TS: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibodies. Circ Shock 33:127, 1991
16. Van der Poll T, Levi M, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174:729, 1991
17. Van der Poll T, Levi M, van Deventer SJH, ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE, ten Cate JW. Differential effects of anti-tumor necrosis factor monoclonal anti-bodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83:446, 1994
18. Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850, 1993
19. Nemerson Y: Tissue factor and hemostasis. Blood 71:1, 1988
20. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: initiation, maintenance and regulation. Biochemistry 30:10363, 1991